Roots Analysis

MARCH 3, 2022

Next Generation Complement Therapeutics – Current Market Landscape. The market is characterized by a mix of well-established and small firms. The pipeline features more than 190 next generation complement therapeutics that are either marketed / are currently being evaluated across different phases of development. Web: [link].

Drug Delivery Systems 52

Drug Delivery Systems Marketing Immune Response Dermatology 52

XTalks

DECEMBER 20, 2023

And this year Eli Lilly stepped into the obesity drug market with its own GLP-1 weight loss drug Zepbound (tirzepatide), which the US Food and Drug Administration (FDA) approved in November of this year. Novo and Lilly are hard at work to expand their manufacturing capacities to meet the skyrocketing demand for their GLP-1 blockbusters.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

The Pharma Data

NOVEMBER 4, 2020

TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well. .

Drugs 52

Drugs Licensing Licensing Sales 52

The Pharma Data

AUGUST 19, 2021

2] These genetic alterations result in hyperactivation of the MET receptor with corresponding cancer cell growth. [3] In the METex14 cohort of the Phase 1 CHRYSALIS study, 19 patients with this genetic alteration received intravenous RYBREVANT TM 1050 mg (for patients who weigh <80 kg) or 1400 mg (for patients who weigh ?80

FDA Approval 52

FDA Approval Dermatology Genetics Development 52

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 52

Production Dermatology Development Containment 52

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 40

Production Dermatology Development Containment 40